The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma
© He et al; licensee BioMed Central Ltd. 2009
Received: 27 November 2008
Accepted: 25 September 2009
Published: 25 September 2009
Gambogic acid (GA) is a major active ingredient of gamboge, a widely used traditional Chinese medicine that has been reported to be a potent cytotoxic agent against some malignant tumors. Many studies have shown that the NF-kappa B signaling pathway plays an important role in anti-apoptosis and the drug resistance of tumor cells during chemotherapy. In this study, the effects and mechanisms of GA and the NF-kappa B inhibitor celastrol on oral cancer cells were investigated.
Three human oral squamous cell carcinoma cell lines, Tca8113, TSCC and NT, were treated with GA alone, celastrol alone or GA plus celastrol. Cytotoxicity was assessed by MTT assay. The rate of apoptosis was examined with annexin V/PI staining as well as transmission electronic microscopy in Tca8113 cells. The level of constitutive NF-kappa B activity in oral squamous cell carcinoma cell lines was determined by immunofluorescence assays and nuclear extracts and electrophoretic mobility shift assays (EMSAs) in vitro. To further investigate the role of NF-kappa B activity in GA and celastrol treatment in oral squamous cell carcinoma, we used the dominant negative mutant SR-IκBα to inhibit NF-kappa B activity and to observe its influence on the effect of GA.
The results showed that GA could inhibit the proliferation and induce the apoptosis of the oral squamous cell carcinoma cell lines and that the NF-kappa B pathway was simultaneously activated by GA treatment. The minimal cytotoxic dose of celastrol was able to effectively suppress the GA-induced NF-kappa B pathway activation. Following the combined treatment with GA and the minimal cytotoxic dose of celastrol or the dominant negative mutant SR-IκBα, proliferation was significantly inhibited, and the apoptotic rate of Tca8113 cells was significantly increased.
The combination of GA and celastrol has a synergistic antitumor effect. The effect can be primarily attributed to apoptosis induced by a decrease in NF-kappa B pathway activation. The NF-kappa B signaling pathway plays an important role in this process. Therefore, combining GA and celastrol may be a promising modality for treating oral squamous cell carcinoma.
Despite improvements in surgery and radiation, the overall survival rate of patients with oral squamous cell carcinoma (OSCC) has not improved over the past two decades. Chemotherapy (pre- or post-surgery) does not appear to be beneficial for local control and survival improvement in the patients with OSCC. Current chemotherapeutic agents have limited efficacy in oral cancer. To overcome this problem, multiple chemotherapeutic agents with different modes of action, used either alone or in combination, have been suggested.
Gambogic acid (GA) is a major active ingredient of gamboge, which has been widely used in traditional Chinese medicine. It is reported that GA possesses diverse biological effects, such as anti-oxidant and anti-infectious activities. Recent pharmacological studies have revealed that GA also has potent cytotoxic and anti-cancer activities in several cancer cell lines [4–8]. However, little is known about the effect of GA on OSCC. In the present study, we investigated and proved that the NF-kappa B pathway was highly activated by GA treatment while inducing cell apoptosis in OSCC. The minimal cytotoxic dose of celastrol effectively suppressed the GA-induced NF-kappa B pathway activation and increased the anti-cancer effect of GA.
GA and celastrol were provided by Calbiochem (Germany). Dimethyl sulfoxide (DMSO) was purchased from Sigma Chemical Company (USA). The compounds were dissolved in DMSO to generate a stock concentration of 100 mM. Subsequent dilutions were made in culture medium. The same proportion of DMSO/culture medium was added to the controls. The final DMSO content was less than 0.1%. RPMI 1640 culture medium and fetal bovine serum (FBS) were obtained from Gibco (USA). 3'-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), bovine serum albumin (BSA) and Hoechst 33342 were purchased from Sigma Chemical Company. PI/RNase Staining Buffer and the Annexin V-FITC Apoptosis Detection Kit I were purchased from BD Pharmingen (USA). The mouse monoclonal antibody against NF-kappa B p65 was purchased from Santa Cruz Biotechnology Incorporation (USA). NE-PER nuclear and cytoplasmic extraction reagents and the LightShift-TM chemiluminescent EMSA kit were purchased from Pierce Biotechnology (USA). Lipofectamine 2000 reagent was purchased from Invitrogen (USA).
Three human oral squamous cell carcinoma cell lines were included in the study. Tca8113 was established in our laboratory. TSCC was a gift from the School of Stomatology, Wuhan University, China. NT was a gift from Nagasaki University, Japan. Cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS, 100 units/ml penicillin and 100 units/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2 [9, 10].
Plasmid and transient transfection
Cells were plated in 6-well plates and transfected with pBabe-SR-IκBα or pBabe using Lipofectamine 2000 reagents according to the manufacturer's instructions (Invitrogen Life Technologies). Six hours after transfection, the complex medium was replaced with RPMI 1640 medium supplemented with 10% (v/v) FBS. After an additional 24 hours of incubation, cells were treated with or without GA.
Cell viability assay
Cells were plated into a 96-well plate at a density of 1 × 103/well and treated with the indicated dose of GA, celastrol or both after 24 hours of incubation. For the cell viability assay, 20 μl of MTT dissolved in PBS (5 mg/ml) was added to each well. The plates were further incubated for 4 hours. The absorbance of each well was measured using an enzyme-linked immunosorbent assay reader at 490 nm after being dissolved in 150 μl of DMSO.
Transmission electron microscopy
Cells were cultured with or without 4 μM GA for 48 hours and then immersed in cacodylate-buffered 2.5% glutaraldehyde at 4°C for 3 hours. Subsequently, cells were washed for 1 hour in 0.1 M cacodylate buffer, pH 7.4, fixed for 1 hour in buffered 1% osmium tetroxide, dehydrated in graded ethanol and embedded in Epon 812. Thin sections (600 Å thick) were stained with uranyl acetate and lead citrate and then observed with a Zeiss EM 900 transmission electron microscopy (Zeiss, Germany) at 50 kV.
DNA content and cell cycle analysis
Cells were treated with 4 μM GA for different periods, trypsinized, washed once with PBS and fixed in 70% ethanol for 2 hours at 4°C. After washing with PBS, fixed cells were incubated with 0.5 ml PI/RNase staining buffer for 15 minutes at room temperature. DNA content and cell cycle status were assessed by FACScan laser flow cytometry (FACSCalibur, Becton Dickinson, USA). The data were analyzed using MODFIT and CELLQUEST software. Apoptotic cells were distinguished from non-apoptotic intact cells by their decreased DNA content, as determined by their lower PI staining intensity in the area below the sub-G0/G1 phase.
Annexin V/PI double-staining assay
Cells (1 × 106) were treated with the indicated dose of GA, celastrol or a combination of both. Apoptotic cells were identified by double supravital staining with recombinant FITC-conjugated annexin V and PI using the Annexin V-FITC apoptosis detection kit according to the manufacturer's instructions. Flow cytometry analysis was performed immediately after supravital staining. Data acquisition and analysis were performed by a Becton Dickinson FACSCalibur flow cytometer using CellQuest software. Cells that were annexin V (-) and PI (-) were considered viable cells. Cells that were annexin V (+) and PI (-) were considered early-stage apoptotic cells. Cells that were annexin V (+) and PI (+) were considered late-stage apoptotic cells. Cells that were annexin V (-) and PI (+) were considered necrotic cells.
Cells were grown on coverslips and cultured for 24 hours. After treatment with the indicated doses of GA, celastrol or both for 12 hours, cells were fixed in 4% paraformaldehyde for 15 minutes, washed in PBS and treated for 15 minutes with PBS containing 0.1% Triton X-100. The cells were then washed, blocked with 10% bovine serum albumin (BSA) for 1 hour at room temperature and incubated at 4°C overnight with NF-kappa B p65 antibody (1:100) diluted in 0.1% BSA. After extensive washing, a 1:200 dilution of FITC-conjugated goat anti-mouse IgG was applied as the secondary antibody for 1 hour at room temperature. Nuclear staining was achieved by incubating cells in Hoechst 33342 for 5 minutes. The slides were then washed and photographed with a laser scanning confocal microscope (TCS SP2, Leica, Germany). The positive control was treated with 50 ng/ml TNF-α (Sigma-Aldrich, USA) for 30 minutes.
Nuclear extracts and electrophoretic mobility shift assays (EMSAs)
Cells (1 × 106) were treated with the indicated doses of GA, celastrol or both, and the nuclear extracts were prepared using NE-PER nuclear and cytoplasm extraction reagents according to the manufacturer's instructions. Synthetic complementary oligonucleotides were 3'-biotinylated using the biotin 3'-end DNA labeling kit (Pierce) according to the manufacturer's instructions and annealed for 2 hours at room temperature. The sequences of the oligonucleotides for NF-kappa B were: 5' - AGT TGA GGG GAC TTT CCC AGG C - 3' and 3' - TCA ACT CCC CTG AAA GGG TCC G - 5'. The binding reaction was carried out for 20 minutes at room temperature in the presence of 50 ng/μl poly (dI-dC), 0.05% Nonidet P-40, 5 mM MgCl2, 10 mM EDTA and 2.5% glycerol in 1× binding buffer (LightShift-TM chemiluminescent EMSA kit), using 20 fM biotin-end-labeled target DNA and 5 μg of nuclear extract. Products were loaded onto native 4% polyacrylamide gels, pre-electrophoresed for 60 minutes in 0.5× Tris borate/EDTA and then submitted to electrophoresis at 100 V before being transferred onto a positively charged nylon membrane (HybondTM-N+) in 0.5× Tris borate/EDTA at 100 V for 30 minutes. Transferred DNA was cross-linked to the membrane at 120 mJ/cm2 and detected using horseradish peroxidase-conjugated streptavidin (LightShift-TM chemiluminescent EMSA kit), according to the manufacturer's instructions.
All assays were repeated three times to insure reproducibility. The significance of results obtained from the control and treated groups was analyzed using the paired Student's t-test. The synergistic effects of GA and celastrol were assessed using factorial ANOVA. Means and standard deviations were calculated. P < 0.05 was regarded as statistically significant.
Effects of GA on cell viability
Apoptotic changes following GA treatment
Activation of the NF-kappa B pathway in GA-induced apoptosis
Synergistic effects of celastrol on GA-induced cytotoxicity
Annexin V/PI double staining indicated that the enhanced cytotoxicity of GA and celastrol resulted from increased apoptosis in Tca8113 cells. Treatment with 0.5 μM celastrol alone did not induce a remarkable degree of cell apoptosis, but upon co-treatment with GA, the number of apoptotic cells significantly increased (P < 0.05 compared to cells treated with GA alone; Figure 4b). Similarly, when GA was combined with a specific NF-kappa B inhibitor, the dominant negative mutant pBabe-SR-IκBα, the proliferation of Tca8113 cells was significantly inhibited compared to cells treated with GA combined with pBabe empty vector (Figure 4c).
Effects of celastrol on GA-induced activation of NF-kappa B
Gambogic acid is a major ingredient of gamboge, a brownish-orange resin exuded from the Asian Garcinia hanburryi tree. The resin has been used as Chinese traditional medicine in China for hundreds of years to treat cancers with little side effect. Recent experiments have demonstrated that GA exhibits a general inhibitory effect against various tumor cell lines [4–6]. However, little information is available in the literature about the effect and mechanism of this compound on the growth of human oral squamous cell carcinomas. In this study, we investigated the effects of GA on the growth of human OSCC cell lines. Our results demonstrate that GA significantly inhibits the viability of OSCC cells and induces their apoptosis in a time- and dose-dependent manner. These results suggest that GA could be a potential chemotherapeutic agent, like many other plant-derived natural compounds .
The transcription factor, NF-kappa B, is well established as a regulator of genes encoding cytokines, cytokine receptors and cell adhesion molecules that drive immune and inflammatory responses. In recent years, NF-kappa B activation has been linked to many aspects of tumorigenesis[13, 14], including the control of apoptosis, cell cycle, differentiation, cell adhesion, cell migration and angiogenesis. Five NF-kappa B family members have been identified in mammalian cells, including p105/p50 (NF-kappa B1), p100/p52 (NF-kappa B2), p65 (REL A), c-REL and RELB, which associate with one another to form various heterodimeric and homodimeric combinations. These proteins are regulated by inhibitors that bind to the inhibitory subunit of the NF-kappa B (I-kappa B) family of ankyrin domain-containing proteins, which include I-kappa B α, I-kappa B β, I-kappa B γ and I-kappa B ε. In a classic NF-kappa B signaling pathway, NF-kappa B resides in the cytoplasm in an inactive state as a heterotrimer consisting of p50, p65 and I-kappa B α subunits. Most carcinogens, inflammatory agents and tumor promoters have been shown to activate NF-kappa B. In response to an activation signal, the I-kappa B α subunit is phosphorylated at serine residues 32 and 36, ubiquitinated at lysine residues 21 and 22, and degraded through the proteasome pathway, thus exposing the nuclear localization signals on the p50-p65 heterodimer. The p65 subunit is then phosphorylated, leading to nuclear translocation and binding to a specific sequence in DNA, which, in turn, results in gene transcription. NF-kappa B regulates the expression of several genes whose products are involved in anti-apoptosis such as Bcl-xL, cIAP and TRAF[16, 17].
It has been found that many chemotherapeutic agents, including taxol, doxorubicin, etoposide, cisplatin and tamoxifen, can activate NF-kappa B. The activation of NF-kappa B can lead to resistance to apoptosis induced by chemotherapeutic agents. Thus, while activating apoptosis, the same agent can also activate NF-kappa B[19, 20], which can prevent apoptosis and block the ability of therapeutic agents to induce cell death. The recognized method of GA's antitumor effect is its ability to bind and interact with the transferrin receptor, and thus induce cell apoptosis. It is also suggested that GA has the ability to repress telomerase activity, which inhibits the proliferation of tumor cells. In this study, we examined the effect of GA on the activation of NF-kappa B in OSCC cells. The results clearly show that GA stimulates nuclear translocation of NF-kappa B p65, up-regulates the DNA binding activity of NF-kappa B, and thus activates the NF-kappa B signaling pathway. Considering the role of NF-kappa B in preventing apoptosis, we could hypothesize that, when treated with GA, an apoptosis inducer, OSCC cells activate the NF-kappa B signaling pathway to resist the apoptosis-inducing effect. This process is similar to the chemotherapy resistance caused by other chemotherapeutic agents.
The pivotal role of the NF-kappa B pathway in the inhibition of cell apoptosis, strongly suggests that NF-kappa B inhibitors would be useful in cancer therapy. In recent years, it has been reported that some agents, mostly plant-derived products, with tumor chemopreventative and chemotherapeutic effects suppress the activation of NF-kappa B. Although some of these agents are known to induce apoptosis, the most likely therapeutic consequence of NF-kappa B inhibition is a reduced apoptotic threshold. Therefore, a reasonable strategy is to use a NF-kappa B inhibitor as an adjuvant with other modalities to sensitize tumor cells to chemotherapeutic agents.
Celastrol is a novel compound that has demonstrated the ability to inhibit cancer progression and down-regulate NF-kappa B activity. It is also a natural product extracted from the traditional Chinese medicine "Thunder of God Vine". Celastrol has been shown to decrease NF-kappa B activity in prostate cancer and leukemia cells[23, 24]. However, it had not previously been evaluated as a potential chemotherapeutic sensitizer for head and neck or other solid tumors. Our results show that a low dose of celastrol (less than 2 μM) had no significant cytotoxic effect on OSCC cells. However, celastrol had a significant synergistic effect on GA-induced apoptosis in OSCC cells. Our combined results show that celastrol decreases NF-kappa B activity stimulated by GA and then decreases the apoptotic threshold of OSCC cells and sensitizes cells to GA-induced apoptosis by inhibiting the NF-kappa B signaling pathway.
In most cases, the efficacy of chemotherapeutic agents is limited due to toxicity and side effects. Therefore, increasing the potency of chemotherapeutic agents remains a worthy goal. Our results show that GA demonstrates antitumor and apoptosis-inducing abilities in oral squamous cell carcinoma cells. GA activates the NF-kappa B pathway while inducing apoptosis, thus blunting its own antitumor effect. Celastrol has a synergistic effect on the GA-induced apoptosis in oral cancer cells by inhibiting the NF-kappa B activity stimulated by GA.
Our study suggests that a minimally toxic dose of celastrol could enhance the cytotoxicity and apoptosis-inducing effect of GA. These results indicate that GA's antitumor effect could be amplified in a minimally toxic way by inhibiting NF-kappa B activity in OSCC cells. Celastrol may also be useful in combination therapies by enhancing the efficacy of chemotherapeutic agents with little toxicity or side effects.
This work was supported by the National Natural Science Foundation of China (30330580,30973343), Project of the Shanghai Science and Technology Committee (08JC1414400,09431902200) and the Shanghai Leading Academic Discipline Project (S30206).
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.View ArticlePubMed
- Blagosklonny MV: How cancer could be cured by 2015. Cell Cycle. 2005, 4: 269-78.PubMed
- Panthong A, Norkaew P, Kanjanapothi D, Taesotikul T, Anantachoke N, Reutrakul V: Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f. J Ethnopharmacol. 2007, 111: 335-40. 10.1016/j.jep.2006.11.038.View ArticlePubMed
- Asano J, Chiba K, Tada M, Yoshii T: Cytotoxic xanthones from Garcinia hanburyi. Phytochemistry. 1996, 41: 815-20. 10.1016/0031-9422(95)00682-6.View ArticlePubMed
- Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L: General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin. 2004, 25: 769-74.PubMed
- Han QB, Cheung S, Tai J, Qiao CF, Song JZ, Xu HX: Stability and cytotoxicity of gambogic acid and its derivative, gambogoic acid. Biol Pharm Bull. 2005, 28: 2335-7. 10.1248/bpb.28.2335.View ArticlePubMed
- Zhao L, Guo QL, You QD, Wu ZQ, Gu HY: Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004, 27: 998-1003. 10.1248/bpb.27.998.View ArticlePubMed
- Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, Jiang S, Zhang HZ: A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA. 2005, 102: 12095-100. 10.1073/pnas.0406731102.PubMed CentralView ArticlePubMed
- Zhang P, Zhang ZY, Zhou XJ, Qiu WL, Chen FA, Chen WT: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer. 2006, 6: 224-10.1186/1471-2407-6-224.PubMed CentralView ArticlePubMed
- Xu Q, Zhang ZY, Zhang P, Chen WT: Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer. 2008, 8: 159-10.1186/1471-2407-8-159.PubMed CentralView ArticlePubMed
- Deorukhkar A, Krishnan S, Sethi G, Aggarwal BB: Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs. 2007, 16: 1753-73. 10.1517/135437188.8.131.523.View ArticlePubMed
- Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998, 16: 225-60. 10.1146/annurev.immunol.16.1.225.View ArticlePubMed
- Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-6. 10.1038/nature04870.View ArticlePubMed
- Bindhu OS, Ramadas K, Sebastian P, Pillai MR: High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck. 2006, 28: 916-25. 10.1002/hed.20437.View ArticlePubMed
- Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 2002, 109 (Suppl): S81-96. 10.1016/S0092-8674(02)00703-1.View ArticlePubMed
- Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998, 281: 1680-3. 10.1126/science.281.5383.1680.View ArticlePubMed
- Chen C, Edelstein LC, Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000, 20: 2687-95. 10.1128/MCB.20.8.2687-2695.2000.PubMed CentralView ArticlePubMed
- Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999, 18: 6853-66. 10.1038/sj.onc.1203239.View ArticlePubMed
- Das KC, White CW: Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem. 1997, 272: 14914-20. 10.1074/jbc.272.23.14914.View ArticlePubMed
- Sethi G, Ahn KS, Pandey MK, Aggarwal BB: celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2007, 109: 2727-35.PubMed
- Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001, 107: 241-6. 10.1172/JCI11991.PubMed CentralView ArticlePubMed
- Setty AR, Sigal LH: Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005, 34: 773-84. 10.1016/j.semarthrit.2005.01.011.View ArticlePubMed
- Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ: Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006, 72: 1311-21. 10.1016/j.bcp.2006.08.014.View ArticlePubMed
- Yang H, Chen D, Cui QC, Yuan X, Dou QP: celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66: 4758-65. 10.1158/0008-5472.CAN-05-4529.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/343/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.